| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
189,490,000 |
| Market
Cap: |
1.14(B) |
| Last
Volume: |
2,547,018 |
Avg
Vol: |
4,440,946 |
| 52
Week Range: |
$4.13 - $7.98 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 16.9 |
| Insider 6 Months : 16.9 |
| Insider 3/6 Months : 32.4 |
|
| Guru Rank Number : 455 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO™ (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
183,601 |
183,601 |
183,601 |
183,601 |
| Total Buy Value |
$1,048,338 |
$1,048,338 |
$1,048,338 |
$1,048,338 |
| Total People Bought |
10 |
10 |
10 |
10 |
| Total Buy Transactions |
10 |
10 |
10 |
10 |
| Total Shares Sold |
11,387 |
11,387 |
11,387 |
506,586 |
| Total Sell Value |
$69,059 |
$69,059 |
$69,059 |
$6,068,300 |
| Total People Sold |
2 |
2 |
2 |
10 |
| Total Sell Transactions |
2 |
2 |
2 |
16 |
| End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Babu Yarlagadda S |
VP Drug Discovery |
• – – |
2009-12-31 |
4 |
D |
$6.46 |
$39,645 |
D/D |
(6,137) |
52,738 |
|
- |
|
| Sheridan William P |
SR VP - CMO |
• – – |
2009-12-01 |
4 |
AS |
$8.17 |
$34,044 |
D/D |
(4,167) |
0 |
|
- |
|
| Sheridan William P |
SR VP - CMO |
• – – |
2009-12-01 |
4 |
OE |
$2.58 |
$10,751 |
D/D |
4,167 |
4,167 |
|
- |
|
| Featheringill William W |
Director |
– • • |
2009-12-01 |
4 |
S |
$8.06 |
$1,186,874 |
I/I |
(147,200) |
231,538 |
|
- |
|
| Featheringill William W |
Director |
– • • |
2009-11-23 |
4 |
S |
$9.56 |
$131,969 |
I/I |
(13,800) |
378,738 |
|
- |
|
| Featheringill William W |
Director |
– • • |
2009-11-20 |
4 |
S |
$9.66 |
$4,238,545 |
I/I |
(439,000) |
392,538 |
|
- |
|
| Babu Yarlagadda S |
VP Drug Discovery |
• – – |
2009-10-26 |
4 |
AS |
$10.85 |
$69,422 |
D/D |
(6,400) |
39,362 |
|
- |
|
| Babu Yarlagadda S |
VP Drug Discovery |
• – – |
2009-10-21 |
4 |
AS |
$10.00 |
$2,000 |
D/D |
(200) |
45,762 |
|
- |
|
| Babu Yarlagadda S |
VP Drug Discovery |
• – – |
2009-10-20 |
4 |
AS |
$10.00 |
$34,000 |
D/D |
(3,400) |
45,962 |
|
- |
|
| Sheridan William P |
SR VP - CMO |
• – – |
2009-10-14 |
4 |
AS |
$8.92 |
$53,540 |
D/D |
(6,000) |
0 |
|
- |
|
| Babu Yarlagadda S |
VP Drug Discovery |
• – – |
2009-09-23 |
4 |
S |
$9.14 |
$182,720 |
D/D |
(20,000) |
49,362 |
|
- |
|
| Mills Mike |
Principal Accounting Officer |
• – – |
2009-07-23 |
4 |
AS |
$8.26 |
$12,390 |
D/D |
(1,500) |
0 |
|
- |
|
| Mills Mike |
Principal Accounting Officer |
• – – |
2009-07-23 |
4 |
OE |
$3.26 |
$4,890 |
D/D |
1,500 |
1,500 |
|
- |
|
| Mills Mike |
Principal Accounting Officer |
• – – |
2009-07-17 |
4 |
AS |
$6.00 |
$5,808 |
D/D |
(968) |
0 |
|
- |
|
| Baker Felix |
10% Owner |
– – • |
2009-06-01 |
4 |
S |
$3.86 |
$593,536 |
I/I |
(153,371) |
3,831,534 |
|
- |
|
| Baker Felix |
10% Owner |
– – • |
2009-06-01 |
4 |
S |
$3.86 |
$271,511 |
I/I |
(70,159) |
1,522,015 |
|
- |
|
| Baker Felix |
10% Owner |
– – • |
2009-06-01 |
4 |
S |
$3.86 |
$18,212 |
I/I |
(4,706) |
120,828 |
|
- |
|
| Baker Felix |
10% Owner |
– – • |
2009-06-01 |
4 |
S |
$3.86 |
$43,308 |
I/I |
(11,191) |
71,997 |
|
- |
|
| Baker Felix |
10% Owner |
– – • |
2009-06-01 |
4 |
S |
$3.86 |
$11,579 |
I/I |
(2,992) |
17,241 |
|
- |
|
| Baker Felix |
10% Owner |
– – • |
2009-05-29 |
4 |
S |
$4.12 |
$524,991 |
I/I |
(126,448) |
3,984,905 |
|
- |
|
| Baker Felix |
10% Owner |
– – • |
2009-05-29 |
4 |
S |
$4.12 |
$240,171 |
I/I |
(57,847) |
1,592,174 |
|
- |
|
| Baker Felix |
10% Owner |
– – • |
2009-05-29 |
4 |
S |
$4.12 |
$16,109 |
I/I |
(3,880) |
125,534 |
|
- |
|
| Baker Felix |
10% Owner |
– – • |
2009-05-29 |
4 |
S |
$4.12 |
$38,305 |
I/I |
(9,226) |
83,188 |
|
- |
|
| Baker Felix |
10% Owner |
– – • |
2009-05-29 |
4 |
S |
$4.12 |
$10,243 |
I/I |
(2,467) |
20,233 |
|
- |
|
| Baker Felix |
10% Owner |
– – • |
2009-05-28 |
4 |
S |
$4.45 |
$1,063,699 |
I/I |
(237,113) |
4,111,353 |
|
- |
|
754 Records found
|
|
Page 26 of 31 |
|
|
0.24 (3.85%) 
